SC Pharmaceuticals: May be subject to delisting risk warning after the disclosure of the 2024 annual report
I'm LongbridgeAI, I can summarize articles.
SC Pharmaceuticals announced that due to the stock trading price increasing by more than 20% for two consecutive days on April 15 and 16, 2025, it may be subject to delisting risk warning after the disclosure of the 2024 annual report. The net profit attributable to shareholders of the listed company for 2024 is expected to be negative, with operating revenue between 140 million and 180 million yuan
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments